Corbus Pharmaceuticals Holdings, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2014; filed February 10, 2015. The filing is an annual report, not a standalone fourth-quarter report. Corbus is a clinical-stage biopharmaceutical company focused on rare inflammatory-fibrotic diseases. Its sole product candidate, Resunab, was not approved or generating revenue.
Business Context and Development Status
- Resunab is an oral CB2-selective anti-inflammatory drug candidate being developed initially for cystic fibrosis and diffuse scleroderma.
- As of year-end, Resunab had completed prior Phase I studies and a Phase IIa neuropathic-pain study conducted by prior licensees, but had not entered Phase IIa trials for cystic fibrosis or scleroderma.
- The company submitted a scleroderma Investigational New Drug application to the FDA on February 5, 2015 and expected to submit the cystic-fibrosis protocol and begin both Phase IIa studies during the second quarter of 2015.
- The April 2014 reverse acquisition resulted in Corbus Pharmaceuticals, Inc. becoming a wholly owned subsidiary of Corbus Pharmaceuticals Holdings, Inc. The company had six full-time employees at year-end.
Financial Results and Position
| Metric | 2014 | 2013 | Change or comment |
|---|---|---|---|
| Revenue | $0 | $0 | No product revenue since inception |
| Research and development expense | $1.256 million | $0.211 million | Increase of approximately $1.045 million |
| General and administrative expense | $1.392 million | $0.347 million | Increase of approximately $1.045 million |
| Total operating expenses | $2.647 million | $0.557 million | Increase of approximately $2.090 million |
| Operating loss | $2.647 million | $0.557 million | Loss increased materially |
| Other income, net | $0.107 million | $(0.045) million | Included a $145,000 gain on debt settlement |
| Net loss | $2.540 million | $0.602 million | Loss increased approximately $1.938 million |
| Basic and diluted loss per share | $0.13 loss | $0.09 loss | Based on weighted-average shares of 20.160 million and 6.965 million |
| Net cash used in operating activities | $2.361 million | $0.367 million | Operating cash use increased |
| Cash and cash equivalents at year-end | $6.262 million | $0.303 million | Increase primarily from equity financing |
| Total debt at year-end | $0.144 million | $0.638 million | All 2014 debt was current and payable in 2015 |
At December 31, 2014, total assets were approximately $6.601 million, total liabilities were $0.738 million, working capital was $5.795 million, and stockholders’ equity was $5.863 million. Cash provided by financing activities was $8.385 million, principally from the issuance of common stock and warrants. The filing states that cash on hand was expected to fund operations through at least December 2015, but that substantial additional capital would be required for clinical development.
Material Changes Versus 2013
- Research and development spending increased primarily because of Resunab manufacturing for clinical trials, consulting, compensation, recruiting, and reduced research grants.
- General and administrative spending increased because of additional employees, investor relations, legal, stock compensation, board compensation, and insurance costs.
- The company completed a private placement of 10.260 million common shares and warrants, generating approximately $8.402 million of net proceeds after offering costs.
- Preferred stock was converted into common stock in connection with the reverse acquisition and financing. Common shares outstanding increased from 6.965 million at December 31, 2013 to 25.938 million at December 31, 2014.
- Debt decreased through repayment and settlement transactions. One vendor settlement produced a $145,000 gain and included cash, common shares, and a warrant.
- Warrants previously classified as a derivative liability were modified and reclassified to equity; no derivative warrant liability remained at year-end.
- Common stock began trading on the OTCQB on October 24, 2014. Fourth-quarter quoted prices ranged from $2.71 to $4.95, although the filing cautions that quotations may not represent actual transactions.
Guidance, Outlook, Risks, and Unusual Items
- Management expected operating losses and expenses to increase substantially as the company initiated clinical trials, expanded research and development, manufactured clinical materials, pursued regulatory approval, added personnel, and operated as a public company.
- Management did not expect FDA approval of Resunab before 2018 at the earliest, and there was no assurance that approval would occur.
- The company intended to seek orphan-drug designation for Resunab in cystic fibrosis and diffuse scleroderma, but designation and any resulting exclusivity were not assured.
- Corbus depended entirely on Resunab and had no approved products, product sales, or other product candidates in development.
- Clinical, regulatory, manufacturing, intellectual-property, reimbursement, financing, product-liability, and competition risks were material. Failure of clinical trials or inability to obtain regulatory approval would substantially impair the company’s ability to generate revenue.
- The company relied on third parties for clinical research, manufacturing, and supply and had no commercial manufacturing or sales infrastructure.
- The filing identifies a continuing need for equity, debt, or collaboration financing. Future financing could dilute existing stockholders, impose restrictive covenants, or require the company to surrender rights to Resunab.
- The company had no material legal proceedings and no material off-balance-sheet arrangements reported.
Most Important Facts for Investors to Verify
- Whether the FDA permitted the planned Resunab Phase IIa studies to proceed and whether the cystic-fibrosis and scleroderma trials were initiated as projected.
- Current cash runway, subsequent financing transactions, dilution, and any changes in outstanding debt or warrant obligations.
- Clinical efficacy and safety results for Resunab; the 2014 filing primarily describes preclinical data and prior studies not designed for the planned indications.
- Status of patent applications, orphan-drug applications, and any licensing or partnering arrangements.
- Whether the company obtained a national exchange listing and whether the authorized reverse stock split was executed.
- Subsequent changes in management’s going-concern assessment, internal controls, operating expenses, and funding requirements.